Physician profile
Daniel Szabo
NPI 1447645817
$4,531.21
in general payments reported to CMS, 2019-2025
30 companies · $879 in 2025
The $879 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.82 · 2020: $371 · 2021: $1,483 · 2022: $719 · 2023: $342 · 2024: $656 · 2025: $879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,842 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,842.15 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,383.42 | 2021-2025 | Interstim, Altaviva |
| Astellas Pharma US INC | $458.08 | 2020-2023 | Myrbetriq |
| Abbvie INC. | $388.01 | 2022-2025 | Botox |
| Calyxo, INC. | $345.87 | 2025 | Cvac Aspiration System |
| Boston Scientific Corporation | $276.50 | 2019-2025 | Lithovue, Lumenis Pulse 120h |
| Axonics, INC. | $176.21 | 2021-2023 | Axonics |
| Bayer Healthcare Pharmaceuticals INC. | $156.07 | 2021-2023 | |
| Neotract INC. | $134.47 | 2020 | |
| Merck Sharp & Dohme LLC | $109.41 | 2022-2024 | Keytruda |
| Sumitomo Pharma America, INC. | $109.11 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $100.41 | 2021-2023 | Erleada |
| Urogen Pharma, INC. | $98.04 | 2020-2024 | |
| Ferring Pharmaceuticals INC. | $83.14 | 2024-2025 | Adstiladrin |
| Immunitybio, INC. | $80.68 | 2024-2025 | |
| Urovant Sciences INC | $80.67 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $71.56 | 2021-2024 | Xiaflex, Aveed |
| Novartis Pharmaceuticals Corporation | $67.29 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $65.55 | 2025 | Imfinzi |
| Hollister Incorporated | $43.25 | 2021 | |
| Antares Pharma, INC. | $43.11 | 2021 | |
| Blue Earth Diagnostics | $42.77 | 2021 | |
| Myovant Sciences INC. | $39.64 | 2021-2022 | |
| Accord Healthcare, INC. | $34.64 | 2022-2024 | |
| Olympus America INC. | $30.67 | 2025 | Itind System |
| Pfizer INC. | $25.34 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $25.24 | 2020-2021 | |
| Progenics Pharmaceuticals, INC. | $19.38 | 2023 | Pylarify |
| Sun Pharmaceutical Industries INC. | $18.75 | 2021 | |
| Dendreon Pharmaceuticals LLC | $12.09 | 2021 | |
| Valencia Technologies Corporation | $11.84 | 2025 | Ecoin Device Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Szabo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.